Reported 6 months ago
A key FDA panel voted against adopting MDMA treatment for PTSD, putting pressure on pharmaceutical companies focused on psychedelics. The FDA's Psychopharmacologic Drugs Advisory Committee found the proposed treatment by Lykos Therapeutics lacked sufficient evidence for efficacy. While the panel's decision is not final, the FDA has until August to make a final determination. Issues with trial data and concerns over abuse potential were highlighted during the evaluation. Analysts are now looking towards other companies for potential breakthroughs in MDMA treatments.
Source: YAHOO